---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024677"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:51:49.650934+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma Q2 FY2023: net loss $4.9M; cash $34.9M; advances three clinical programs

## Summary
- Net loss $4.9M ($0.11/sh) vs net income $1.0M in prior-year quarter; operating loss $5.1M.
- R&D expenses rose to $3.3M from $0.6M due to PK studies for GTX-104, -102, -101.
- Cash & short-term investments $34.9M as of Sep 30, 2022, down from $43.7M at Mar 31, 2022; runway through at least Mar 2024.
- FDA Type C meeting on GTX-104 Phase 3 design expected by end of 2022/early Q1 2023; GTX-102 and GTX-101 PK topline results by end of 2022.
- Vimal Kavuru appointed Chairman of the Board.

## SEC filing metadata
- accession: 0000950170-22-024677
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017022024677/0000950170-22-024677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017022024677/acst-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024677
- JSON: https://secwatch.observer/filing/0000950170-22-024677.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024677.txt

## Key facts
- Earnings Releases
  Grace Therapeutics, Inc. reported financial results for the second quarter ended September 30, 2022.
  - Period: the second quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017022024677/0000950170-22-024677-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.